ERBB3
Receptor tyrosine-protein kinase erbB-3
As of the edition of 20 October 2026, ERBB3 (receptor tyrosine-protein kinase erbB-3, UniProt P21860) has 24 drugs tested at it and 27 companies on the list, 12 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21860
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 23
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Digestive system; Hormones; Urinary and reproductive; Pregnancy and women's health; Nervous system
- Registered trials of its drugs
- 228
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 6 |
| Went quiet | 7 |
| Stopped | 8 |
| Status not established | 1 |
| Total | 24 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vandetanib | Marketed | Phase 3 | none listed |
| Patritumab deruxtecan | Active | Phase 3 | none listed |
| Poziotinib | Stopped | Phase 3 | none listed |
| Seribantumab | Stopped | Phase 2 | none listed |
| Sapitinib | Active | Phase 2 | none listed |
| CDX-3379 | Stopped | Phase 2 | none listed |
| Duligotuzumab | Went quiet | Phase 2 | none listed |
| Elgemtumab | Went quiet | Phase 2 | none listed |
| Patritumab | Stopped | Phase 3 | none listed |
| MM-111 | Stopped | Phase 2 | none listed |
| Tarloxotinib | Stopped | Phase 2 | none listed |
| YL202 | Active | Phase 3 | none listed |
12 of 24 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 12 |
| Route B | 2 |
| Engaged | 10 |
| Undetermined | 3 |
| Total on the list | 27 |
| Company | Route |
|---|---|
| Roche | Route A |
| Novartis | Route A |
| Hanmi Pharmaceutical | Route A |
The other 24 companies at ERBB3
In the product27 companies in all; 24 are not named here, and no score is.
See the 27 companies at ERBB3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.